OIPE JC56
APR 25 2005
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	10/817,334
Filing Date	April 2, 2004
First Named Inventor	Hammock, Bruce D.
Art Unit	1654
Examiner Name	Not yet assigned
Attorney Docket Number	02307W-131010US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No.[1]	Document Number: Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ADK	1.	5,445,956 A	08-29-1995	Hammock et al.	
	2.	5,637,113 A	06-10-1997	Tartaglia et al.	
	3.	6,150,415 A	11-21-2000	Hammock et al.	
	4.	6,287,285 B1	09-11-2001	Michal et al.	
	5.	6,290,722 B1	09-18-2001	Wang	
	6.	6,299,604 B1	10-09-2001	Ragheb et al.	
	7.	6,322,847 B1	11-27-2001	Zhong et al.	
	8.	6,335,029 B1	01-01-2002	Kamath et al.	
ADK	9.	6,351,506 B1	02-26-2002	Lewicki	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
								☐
								☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known	
Application Number	10/817,334
Filing Date	April 2, 2004
First Named Inventor	Hammock, Bruce D.
Art Unit	1654
Examiner Name	Not yet assigned
Attorney Docket Number	02307W-131010US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
ADK	10.	ARAND, M. et al., "Sequence similarity of mammalian epoxide hydrolases to the bacterial haloalkane dehalogenase and other related proteins" FEBS Lett., 338:251-256 (1994)	
	11.	ARGIRIADI, M.A. et al., "Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation" J. Biol. Chem., 275:15265-15270 (2000)	
	12.	ARGIRIADI, M.A. et al., "Detoxification of encironmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase" Proc. Natl. Acad. Sci. USA, 96:10637-10642 (1999)	
	13.	BARDIN, C. W. (ed.), Current Therapy In Endocrinology And Metabolism, 6th Edition, Mosby - Year Book, Inc., St. Louis, MO 1997	
	14.	BEETHAM, J. et al., "cDNA cloning and expression of a soluble epoxide hydrolase from human liver" Arch. Biochem. Biophys., 305(1):197-201 (1993)	
	15.	BEETHAM, J. et al., "Gene evolution of epoxide hydrolases and recommended nomenclature" DNA Cell Biol., 14(1):61-71 (1995)	
	16.	CAMPBELL, W.B., "New role for epoxyeicosatrienoic acids as anti-inflammatory mediators" Trends Pharmacol. Sci., 21:125-127 (2000)	
	17.	CAPDEVILA, J.H. et al., "Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase" J. Lipid. Res., 41:163-181 (2000)	
	18.	CARROLL, M.A. et al., "A new class of lipid mediators: cytochrome P450 arachidonate metabolites" Thorax, 55:S13-16 (2000)	
	19.	CHIASSON, J. et al., "The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus" Ann. Intern. Med., 121:928-935 (1994)	
	20.	CONIFF, R. et al., "Multicenter, placebo-controlled trial comparing acarbose (BAY g5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus" Am. J. Med., 98:443-451 (1995)	
	21.	CONIFF, R. et al., "Acarbose: a review of US clinical experience" Clin. Ther., 19:16-26 (1997)	
	22.	DEFRONZO, R. et al. (eds.), "Introduction" Diabetes Reviews, 5(4):293 (1997)	
	23.	DUDDA, A. et al., "Lipid oxidation products in ischemic porcine heart tissue" Chem. Phys. Lipids, 82:39-51 (1996)	
	24.	FANG, X., et al., "Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels" Am. J. Physiol. Heart Circ. Physiol. 287:H2412-H2420 (2004)	
	25.	FISSLTHALER, B. et al., "Cytochrome P450 2C is an EDHF synthase in coronary arteries" Nature, 401:493-497 (1999)	
ADK	26.	FRETLAND, A.J. et al., "Epoxide hyrolases: biochemistry and molecular biology" Chem. Biol. Intereract., 129:41-59 (2000)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/817,334
				Filing Date	April 2, 2004
				First Named Inventor	Hammock, Bruce D.
				Art Unit	1654
(use as many sheets as necessary)				Examiner Name	Not yet assigned
Sheet	3	of	5	Attorney Docket Number	02307W-131010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
ADK	27.	FUKUSHIMA, A. et al., "Cardiovascular effects of leukotoxin (9,10-epoxy-12-octadecenoate) and free fatty acids in dogs" Cardiovasc. Res., 22:213-218 (1988)	
	28.	GIBSON, G.G. and SKETT, P., Introduction to Drug Metabolism, Second Ed., Chapman and Hall, New York pp. 199-210 (1994)	
	29.	GRANT, D. et al., "Molecular cloning and expression of murine liver soluble epoxide hydrolase" J. Biol. Chem., 268(23):17628-17633 (1993)	
	30.	HAFFNER, S., "Management of dyslipidemia in adults with diabetes" Diabetes Care, 21:160-178 (1998)	
	31.	HAMMOCK, B.D. et al., "Chapter 3.18: Epoxide Hyrolases" *in* Comprehensive Toxicology. Oxford: Pergamon Press pp. 283-305 (1977)	
	32.	HONIG and INGRAM, "Chronic Bronchitis, Emphysema, and Airways Obstruction" *in* Harrison's Principles of Internal Medicine, (Fauci et al., Eds.), 14th Ed., McGraw-Hill, New York, pp. 1451-1460 (1998)	
	33.	ISHIZAKI, T. et al., "Leukotoxin, 9,10-epoxy-12-octadecenoate causes pulmonary vasodilation in rats" Am. J. Physiol., 268:L123-128 (1995)	
	34.	ISHIZAKI, T. et al., "Leukotoxin, 9,10-epoxy-12-octadecenoate causes edematous lung injury via activation of vascular nitric oxide synthase" Am. J. Physiol., 269:L65-70 (1995)	
	35.	ISHIZAKI, T. et al., "Endothelin-1 potentiates leukotoxin-induced edematous lung injury" J. Appl. Physiol., 79:1106-1611 (1995)	
	36.	IWAMOTO, Y. et al., "Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone" Diabet. Med., 13:365-370 (1996)	
	37.	KIM, I., et al., "Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility" J. Med. Chem. 47:2110-2122 (2004)	
	38.	KWITEROVICH, P., "State-of-the-art update and review: clinical trials of lipid-lowering agents" Am. J. Cardiol., 82(12A):3U-17U (1998)	
	39.	MAHLER, R. et al., "Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment" J. Clin. Endocrinol. Metab., 84:1165-71 (1999)	
	40.	MCELROY, N.R, et al., "QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds" J. Med. CHem. 46:1066-1080 (2003)	
	41.	MOGHADDAM, M.F. et al., "Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase" Nat. Med., 3:562-567 (1997)	
	42.	MORISSEAU, C., et al., "Potent urea and carbamate inhibitors of soluble epoxide hydrolases" Proc. Natl. Acad. Sci. USA, 96:8849-8854 (1999)	
ADK	43.	MORISSEAU, C., et al., "Inhibition of microsomal epoxide hydrolases by ureas, amides, and amines" Chem. Res. Toxicol. 14:409-415 (2001)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/817,334
				Filing Date	April 2, 2004
				First Named Inventor	Hammock, Bruce D.
				Art Unit	1654
(use as many sheets as necessary)				Examiner Name	Not yet assigned
Sheet	4	of	5	Attorney Docket Number	02307W-131010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
ADK	44.	MORISSEAU, et al., "Structural refinement of inhibitors of urea-based soluble epoxide hydrolases" Biochem. Pharm., 63:1599-1608 (2002)	
	45.	NAKAGAWA, Y., et al., "3-D QSAR analysis of inhibition of murine soluble epoxide hydrolase (MsEH) by benzoylureas, arylureas, and their analogues" Bioorg. Med. Chem. 8:2663-2673 (2000)	
	46.	NEWMAN, J.W. et al., "Evaluation of fish models of soluble epoxide hydrolase inhibition" Environ. Health Perspect., 109:61-66 (2001)	
	47.	NODE, K. et al., "Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids" Science, 285:1276-1279 (1999)	
	48.	OESCH, F. et al., "Mammalian epoxide hydrases: inducible enzymes catalyzing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds" Xenobiotica, 3:305-340 (1973)	
	49.	OLTMAN, C.L. et al., "Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation" Circ Res., 83:932-939 (1998)	
	50.	OZAWA, T. et al., "Existence of leukotoxin 9,10-epoxy-12-octadecenoate in lung lavages from rats breathing pure oxygen and from patients with the adult respiratory distress syndrome" Am. Rev. Respir. Dis., 137:535-540 (1988)	
	51.	REYNOLDS, H.Y., "Interstitial lung diseases" *in* Harrison's Principles of Internal Medicine, (Fauci et al., Eds.), 14th Ed., McGraw-Hill, New York, pp. 1460-1466 (1998)	
	52.	SAKAI, T. et al., "Leukotoxin, 9,10-epoxy-12-octadecenoate inhibits mitochondrial respiration of isolated perfused rat lung" Am. J. Physiol., 269:L326-331 (1995)	
	53.	SINAL, C.J. et al., "Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation" J. Biol. Chem., 275:40504-405010 (2000)	
	54.	SPEIZER, "Environmental Lung Diseases," Harrison's Principles of Internal Medicine, (Fauci et al., Eds.), 14th Ed., 1998, McGraw-Hill, New York, pp. 1429-1436	
	55.	TURNER, N. et al., "Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutics possibilities" Prog. Drug Res., 51:33-94 (1998)	
	56.	UNITED KINGDOM PROSPECTIVE DIABETES STUDY GROUP, "UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes", Diabetes Care, 21: 87-92 (1998)	
	57.	WALTER, E. et al., "Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data" Pharm. Res., 12: 360-365 (1995)	
	58.	WATANABE, K. et al., "Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line caco-2" Biol. Pharm. Bull., 25:1345-1350 (2002)	
	59.	WATANABE, T., et al., "In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea" Drug Metab. Dispos. 31(7):846-853 (2003)	
ADK	60.	WEINTRAUB, N.L. et al., "Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids" Am. J. Physiol., 277:H2098-2108 (1992)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/817,334
				Filing Date	April 2, 2004
				First Named Inventor	Hammock, Bruce D.
				Art Unit	1654
(use as many sheets as necessary)				Examiner Name	Not yet assigned
Sheet	5	of	5	Attorney Docket Number	02307W-131010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
ADK	61.	YU, Z. et al., "Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids" Circ. Res., 87:992-998 (2000)	
ADK	62.	ZELDIN, D.C., et al., ""Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase" J. Biol. Chem., 268:6402-6407 (1993)	
ADK	63.	ZHAO, X., et al., "Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage" J. Am. Soc. Nephrol. 15:1244-1253 (2004)	
ADK	64.	ZHENG, J. et al., "Leukotoxin-Diol: a putative toxic mediator involved in acute respiratory distress syndrome" Am. J. Respir. Cell Mol. Biol., 25:434-438 (2001)	

Examiner Signature	/Andrew D. Kosar/	Date Considered	12/21/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/817,334
				Filing Date	April 2, 2004
				First Named Inventor	Hammock, Bruce D.
				Art Unit	1654
(Use as many sheets as necessary)				Examiner Name	Kosar, Andrew D.
Sheet	1	of	1	Attorney Docket Number	02307W-131010US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (if known)				
~~———~~	~~1~~	~~WO~~	~~00/48599~~		~~8/24/00~~	Regents of University of California	~~———~~	☐
~~———~~	~~2~~	~~WO~~	~~00/061597~~	~~A2~~	~~7/24/03~~	Regents of University of California	~~———~~	☐

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
ADK	3	YAMADA, T., et al., "Biochemical Evidence for the Involvement of Tyrosine in Epoxide Activation During the Catalytic Cycle of Epoxide Hydrolase," JOURNAL OF BIOLOGICAL CHEMISTRY, 275(39): 23082-20388, Vol. 275, (28 July 2000).	☐
ADK	4	WATANABE, T., et al., "Rapid Determination of Soluble Epoxide Hydrolase Inhibitors in Rat Hepatic Microsomes by High-Performance Liquid Chromatography With Electrospray Tandem Mass Spectrometry," ANALYTICAL BIOCHEMISTRY, 299(2): 227-234, (2001).	☐

Examiner Signature	/Andrew D. Kosar/	Date Considered	12/21/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.